New Articles

get your shot

Yes, you can get bivalent COVID-19 and flu shots at the same time

The FDA recently authorized COVID-19 bivalent boosters and the CDC recommended them for everyone 12 years and older.

Q: What is a “bivalent” booster?

A: Both Moderna and Pfizer boosters contain mRNA that code for the spike protein of the original Wuhan-hu-1 strain and the spike protein of the Omicron variant lineages BA.4 and BA.5. The BA.4 and BA.5 variants differ in several ways, but their spike proteins are identical.

Q: Why did they not produce just an Omicron monovalent vaccine?

A: It was important to include the original Wuhan-hu-1 strain as the virus may mutate out of the Omicron lineage. We do not know what variant may come next and it may be more like the original than Omicron. 

Q: Is the bivalent booster necessary?

A: It is unknown. The original mRNA vaccines are very good at preventing hospitalization and death but not as good at preventing milder infections. The vaccines could be better as about forty percent of hospitalization are among the vaccinated. Clinical trials demonstrate that people boosted with bivalent vaccines produce antibodies good at neutralizing Omicron variants. Hopefully, these antibodies will decrease serious illnesses even further. Trials studying effectiveness are underway.

Q: Why do some vaccinated people still end up being hospitalized?

A: To be clear, nearly 70 percent of the U.S. population has received their primary COVID-19 vaccine series. The 30 percent who are unvaccinated make up 60 percent of the hospitalizations. Those vaccinated individuals who develop severe disease are more likely to be 85 years or older or have other health conditions that place them at risk. Their health conditions tend to be so serious that even the common cold may put them in the hospital. There are also “healthy” individuals who appear to be genetically vulnerable to COVID-19. Still, everyone does better vaccinated than not.

Q: Who can receive a bivalent booster?

A: Anyone 12 years and older who received their primary series if it is at least 2 months since their last COVID-19 vaccine. The Pfizer bivalent is approved for those 12 and older and the Moderna bivalent is approved for those 18 and older. A bivalent vaccine has not been approved for younger children.

Q: What if I just had COVID-19?

A: It is likely you had the Omicron variant and so it is reasonable to wait three months to get boosted, as natural immunity is protective for at least that long. But if you want, it is fine to receive the booster as soon as you are out of isolation.

Q: Can I receive other vaccines like the flu shot at the same time?

A: YES! It is a great idea to get both the bivalent COVID-19 and flu shots at the same time.  The one exception is for young men under 30 who received the monkeypox vaccine; it is best for them to wait four weeks before receiving a COVID-19 vaccine to minimize the rare risk of inflammation of the heart.

Megan Berman
Richard Rupp
Vaccine Smarts is written by Sealy Institute for Vaccine Sciences faculty members Drs. Megan Berman, an associate professor of internal medicine, and Richard Rupp, a professor of pediatrics at the University of Texas Medical Branch. For questions about vaccines, email vaccine.smarts@utmb.edu.
  • COVID-19 Clinical Task Force: Revised COVID-19 precautions take effect on Sept. 29, 2022

    As a result of the high levels of vaccine- and infection-induced immunity and the availability of effective treatments and prevention tools, along with the local alert designation of GREEN (low COVID risk) per the CDC data tracker, new revised COVID-19 recommendations will be in effect beginning Sept. 29. The changes are detailed in this latest message from the COVID-19 Task Force. This message is intended for UTMB employees, who must be logged onto the UTMB network to access the full text. Thank you.

  • Woman with face surgical mask getting arm swabbed

    El nuevo refuerzo de la vacuna bivalente

    Un nuevo refuerzo de la vacuna contra el COVID, diseñado para proteger contra las variantes actualmente dominantes BA.4/BA.5 esta disponible en UTMB.

  • Woman with face surgical mask getting arm swabbed

    New bivalent COVID vaccine booster

    A new COVID booster—designed to protect against the now-dominant BA.4/BA.5 strains will be available at UTMB Health starting Sept. 13. Learn about the new booster and who qualifies for it.

  • Sept. 6, 2022: COVID-19 Clinical Task Force updates visitation, social distancing and masking requirements

    Due to the declining rates of COVID-19 infections in our region, modifications have been made to the UTMB social distancing and masking requirements and visitation policy, effective September 7, 2022. The changes are detailed in this latest message from the COVID-19 Task Force. This message is intended for UTMB employees, who must be logged onto the UTMB network to access the full text. Thank you.

  • Two female students studying

    Novavax's COVID-19 Vaccine

    The U.S. Centers for Disease Control and Prevention recently approved Novavax’s COVID-19 vaccine for emergency use in adolescents ages 12 through 17.

  • COVID-19 update on the current wave, test-to-treat program and new vaccination option

    The UTMB COVID-19 Clinical Task Force shared updates on high test positivity rates among patients tested at UTMB, information on the successful COVID-19 test-to-treat program, and the new Novavax vaccine, an effective option for those reluctant or unable to get mRNA vaccines.

  • Vaccines available for children ages 6 months to 5 years

    Many parents, caregivers and clinicians have been waiting for a COVID-19 vaccine for younger children. Now that the CDC has approved the vaccine for children ages 6 months to 5 years, UTMB will begin offering the vaccine at our pediatric clinics beginning Monday, June 27.

  • Vaccines available for ages 6 months to 5 years

    Moderna and Pfizer-BioNTech COVID-19 Vaccines have now been authorized for children down to 6 months of age. On June 18, CDC endorsed that all children 6 months through 5 years of age should receive a COVID-19 vaccine.

  • June 23, 2022: Changes in testing policies for procedures, hospital admissions

    During the past few weeks, we have noted a rapid increase in COVID-19 test positivity in our community—now at 30%—and a gradually increasing inpatient census. As a result of these recent developments, changes in COVID-19 testing policies are being made...

  • Clinical Task Force: Updated COVID safety measures to take effect on June 7

    Due to a continued increase in COVID infections in the community this week (test positivity of >20%) together with a modest increase in COVID-related hospitalizations and rising infection among employees and students, new COVID precautions are being implemented effective June 7, 2022.

  • COVID-19 Clinical Task Force: Modifications to precautions due to increasing number of infections

    The rate of COVID infection has continued to increase in our region as well as among our patients and UTMB workforce. Although rates of severe infection and hospitalization due to COVID remain stable and low, caution is advised to keep our employees and patients safe from COVID infection during this current wave. The following COVID precautions are effective immediately. If the rates of COVID admissions and infections among our workforce increase further, additional precautions may be implemented.

  • Vaccination Task Force: CDC recommends FDA-approved single-dose booster for children ages 5-11

    On May 17, 2022, the U.S. Food and Drug Administration authorized the use of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age at least five months after completing a primary series with the Pfizer-BioNTech COVID-19 vaccine. (See the FDA announcement.) The Centers for Disease Control and Prevention approved the booster for this age group on May 19, 2022. CDC now recommends that children ages 5 through 11 years should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series. (See the CDC announcement.)

  • FDA has approved single-dose booster for children ages 5-11

    A single booster dose of the Pfizer-BioNTech COVID-19 Vaccine has been approved for children 5 through 11 years of age, at least five months after completing a primary series with the Pfizer-BioNTech COVID-19 vaccine

  • Clinical Task Force: An Update on COVID-19—May 12, 2022

    There has been a modest increase in the COVID-19 positivity rate in our community, which has ranged from 6% to 11% in the past week. While the COVID-19 hospitalization rate has increased only slightly, it may increase further over the next two to three weeks. Currently, UTMB is not planning any immediate changes to our COVID-19 precautions. However, if COVID-19 positivity and hospitalization rates increase, changes in precautions may be necessary.

  • COVID-19 Vaccine Task Force: Revised masking guidelines effective immediately—April 22, 2022

    As a result of the continued low rates of COVID-19 infection in our community and among UTMB faculty, staff and students—as well as very low hospitalization rates—the following modifications to the masking policy will be implemented effective immediately, April 22, 2022. (Please note that we will continue to monitor infection and hospitalization rates in our region; therefore, these policies are subject to change on short notice, based on the most current data).